{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT06318871","nct_id":"NCT06318871","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06318871. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will be enrolled in a staggered fashion into a 3+3 dose de-escalation design per protocol to establish a maximum tolerated dose (MTD) of CIML NK Cells. Dose will start at Dose Level 0.\n\n* Baseline visit.\n* Day -7: Apheresis for autologous NK cell collection.\n* Days -6 through -2: Predetermined dose of standard of care lymphodepleting chemotherapy per protocol.\n* Days 0: Predetermined dose of CIML NK Cell Therapy infusion 1x daily administered in-clinic or hospital.\n* Days 1 through 8: Low dose IL-2 every other day\n* Day 28 and then ever 2-3 months: CT/MRI/PET\n* In-clinic visit every 3 months with CT, MRI, or PET scan.\n* End of Treatment: in-clinic visit\n* Follow Up: every 4 months in-clinic, by telephone, or remotely.\n* If 2 or more out of 5 participants experience dose-limiting toxicities (DLTs), subsequent dose will be de-escalated to Dose Level -1.","label":"Dose Level 0: CIML NK + low dose IL-2","type":"EXPERIMENTAL"},{"description":"Participants will complete:\n\n* Baseline visit.\n* Day -7: Apheresis for autologous NK cell collection.\n* Days -6 through -2: Predetermined dose of standard of care lymphodepleting chemotherapy per protocol.\n* Days 0: Predetermined dose of CIML NK Cell Therapy infusion 1x daily administered in-clinic or hospital.\n* Days 1 to 8: low dose IL-2 every other day\n* Day 28 and then ever 2-3 months: CT/MRI/PET\n* In-clinic visit every 3 months with CT, MRI, or PET scan.\n* End of Treatment: in-clinic visit\n* Follow Up: every 4 months in-clinic, by phone, or remotely.\n* If 1 or less DLTs are observed, this will be the maximum tolerated dose. If 2 or more DLTs are observed, accrual will stop.","label":"Dose Level -1: CIML NK + low dose IL-2","type":"EXPERIMENTAL"}],"collaborators":["Kidney Cancer Association"],"completion_date":{"date":"2031-07-28","type":"ESTIMATED"},"conditions":["Renal Carcinoma","Renal Cell Carcinoma","Urothelial Carcinoma","Chromophobe Renal Cell Carcinoma","Translocation Renal Cell Carcinoma"],"enrollment":{"count":5,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Cytokine Induced Memory-like Natural Killer (CIML NK) Cells","otherNames":["NK Cells"],"type":"BIOLOGICAL"},{"name":"Interleukin-2 (IL-2)","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-23","lead_sponsor":"Dana-Farber Cancer Institute","official_title":"A Phase 0 Pilot Study of Memory-like Natural Killer (NK) Cell Immune Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["EARLY_PHASE1"],"primary_completion_date":{"date":"2027-02-28","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Feasibility Failure Rate (FFR)","timeFrame":"Observation period up to 98 days."}],"references":[],"start_date":{"date":"2024-08-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma","url":"https://clinicaltrials.gov/study/NCT06318871"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06318871"}